A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.

Blood Adv · 2023 · PMC10425682 · PMID 37171402

Europe PMC DOI

hedged sentence

0.4100

closest p · 8.2× alpha

0.4100

boldest claim

The sentences

did not reach statistical significanceP = .41not close (p > 0.1)

Numerically a greater number of patients receiving CPX-351 underwent transplantation, although this did not reach statistical significance (53/105 [51%] vs 36/82 [44%]; P = .41).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.